Will methotrexate therapy stop further bone erosion in a patient with rheumatoid arthritis who is also receiving prednisolone 10 mg daily?

Methotrexate Can Slow But Not Completely Stop Bone Erosion in Rheumatoid Arthritis

Methotrexate will significantly slow the progression of bone erosion in rheumatoid arthritis, but it does not completely stop it—the disease-modifying effect reduces radiographic progression to less than 0.5-1 Sharp units per year, which is clinically meaningful but not zero. 1, 2

What the Evidence Shows About Bone Protection

The FDA drug label is explicit and sobering: "Although methotrexate clearly ameliorates symptoms of inflammation (pain, swelling, stiffness), there is no evidence that it induces remission of rheumatoid arthritis nor has a beneficial effect been demonstrated on bone erosions and other radiologic changes which result in impaired joint use, functional disability, and deformity." 1 This statement reflects the reality that methotrexate slows but does not halt erosive disease.

However, more recent systematic analysis provides a more nuanced picture. A 2021 systematic review found that methotrexate can reduce the risk of bone erosion progression, with radiographic scores showing progression of less than 0.5-1 Sharp unit per year in treated patients 2. This represents clinically significant slowing of joint destruction, even if complete arrest is not achieved.

The Critical Role of Combination Therapy with Prednisolone

Your patient's concurrent use of prednisolone 10 mg daily is actually protective and enhances methotrexate's bone-protective effects. This is crucial information:

• The CAMERA-II trial demonstrated that adding 10 mg prednisolone daily to methotrexate resulted in significantly lower erosion scores at 2-year follow-up compared to methotrexate alone (median erosion score 0 vs 0-2, p=0.002) 3

• This combination also reduced the need for biologic DMARDs (31% vs 50% initiated biologics, p=0.003) 3

• The mechanism involves downregulation of RANK (receptor activator of nuclear factor-κβ) expression on monocytes, which are osteoclast precursors. Methotrexate plus low-dose prednisolone decreases both RANK surface expression and osteoclast resorptive activity 4

• Another randomized trial (CAMERA-II) confirmed that methotrexate plus 10 mg prednisolone daily produced less erosive joint damage after 2 years compared to methotrexate alone 5

Practical Expectations for Your Patient

With methotrexate plus prednisolone 10 mg daily, your patient should expect:

1. Significant slowing of erosion progression to near-zero levels in many cases, particularly if disease activity is well-controlled
2. Better outcomes than methotrexate monotherapy due to the synergistic bone-protective effects
3. Continued need for monitoring because some erosion may still occur, especially if disease activity flares

Important Caveats About Prednisolone Use

The evidence supports short-term bridging therapy with prednisolone rather than indefinite use. The ARCTIC trial showed that 84% of patients successfully discontinued prednisolone after 7 weeks of bridging therapy, with 80% not requiring restart 6. However, your patient is on continuous 10 mg daily, which differs from guideline-recommended bridging strategies.

The CAMERA-II protocol used prednisolone 10 mg daily initially but aimed to taper and stop if possible 3. Continuous long-term use at 10 mg daily carries glucocorticoid-related risks, though the CAMERA-II follow-up found no significant increase in glucocorticoid-related comorbidities over 11.8 years 3.

Monitoring Strategy

Given that complete arrest of erosion is unlikely, serial radiographic monitoring remains essential:

• Baseline radiographs should be obtained
• Repeat imaging at 6-12 months initially, then annually if stable
• Any progression >0.5-1 Sharp units/year should prompt treatment intensification
• Consider adding or switching to biologic DMARDs if erosions progress despite optimal methotrexate dosing (20-25 mg/week) 7

Bottom Line

Methotrexate combined with prednisolone 10 mg daily will substantially slow bone erosion—often to clinically insignificant levels—but cannot guarantee complete cessation. The combination is more effective than methotrexate alone for preventing structural damage. However, the goal should be to taper prednisolone to the lowest effective dose or discontinue it entirely while maintaining disease control with methotrexate, adding biologics if needed when erosions progress.